Efficacy of combined icotinib and pemetrexed in EGFR mutant lung adenocarcinoma cell line xenografts.

abstract：BACKGROUND:Tumor recurrence or residual tumor after targeted therapy is common in patients with advanced non-small cell lung cancer (NSCLC). There is a lack of high-level evidence on which type of treatment should be employed for these patients and the role of salvage surgery has not been well reported in the literatur...

journal_title：Thoracic cancer

authors： Song W,Di S,Liu J,Fan B,Zhao J,Zhou S,Chen S,Dong H,Yue C,Gong T

更新日期：2020-04-01 00:00:00

abstract：:Bronchomediastinal fistula is an extremely rare complication resulting from diseases such as mediastinitis or mediastinal malignancies. In patients with lung cancer, bronchomediastinal fistula formation has rarely been reported, except during post-chemotherapy or post-radiation therapy complications. An 84-year-old vi...

journal_title：Thoracic cancer

authors： Song SH,Oh YJ,Chae SM,Lee J

更新日期：2013-08-01 00:00:00

abstract：BACKGROUND:Advanced non-small cell lung cancer (NSCLC) has a high mortality rate and poor prognosis. However, outcomes have gradually improved after the introduction of novel immunotherapies, including immune checkpoint inhibitors (ICIs). Although programmed death-ligand 1 (PD-L1) expression in tumor tissues is a known...

journal_title：Thoracic cancer

authors： Katakura S,Kobayashi N,Hashimoto H,Kamimaki C,Tanaka K,Kubo S,Nakashima K,Teranishi S,Manabe S,Watanabe K,Horita N,Hara Y,Yamamoto M,Kudo M,Piao H,Kaneko T

更新日期：2020-10-01 00:00:00

abstract：BACKGROUND:Many randomized clinical trials have demonstrated that epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) are advantageous over standard chemotherapy, either as front-line treatment or as further management of patients with EGFR mutation-positive non-small-cell lung cancer (NSCLC). Howev...

journal_title：Thoracic cancer

authors： Sun H,Sun X,Zhai X,Guo J,Liu Y,Ying J,Wang Z

更新日期：2016-01-01 00:00:00

abstract：:Multiple lung nodules caused by pneumonia are a rare presentation in intercostal hemangioma. We experienced a case with intercostal hemangioma that presented with multiple metastasized lung nodules caused by pneumonia, which had previously been misdiagnosed as sarcoma six months earlier. The patient was treated for pn...

journal_title：Thoracic cancer

authors： Mei L,Shi H,Che G

更新日期：2010-11-01 00:00:00

abstract：:Patients with EGFR-mutated non-small cell lung cancer (NSCLC) exhibit resistance to EGFR-tyrosine kinase inhibitors (TKIs) within 9-14 months of therapy. Recently, EGFR-mutated NSCLC has demonstrated the potential for heterogeneity; therefore, the manner of clonal heterogeneity may impact the duration of progression-f...

journal_title：Thoracic cancer

authors： Okuma Y,Morikawa K,Tanaka H,Yokoyama T,Itani H,Horiuchi K,Nakagawa H,Takahashi N,Bessho A,Soejima K,Kishi K,Togashi A,Kanai Y,Ueda K,Horimoto K,Matsutani N,Seki N

更新日期：2019-02-01 00:00:00

abstract：BACKGROUND:The aim of this study was to evaluate the prevalence, risk factors, and survival of lung cancer in patients with idiopathic pulmonary fibrosis (IPF). METHODS:IPF with lung cancer from tertiary hospitals consisted of 1685 patients who had been diagnosed between 2003 and 2007. We reviewed their medical record...

journal_title：Thoracic cancer

authors： Lee KJ,Chung MP,Kim YW,Lee JH,Kim KS,Ryu JS,Lee HL,Park SW,Park CS,Uh ST,Lee YC,Park SJ,Kim KH,Jeon YJ,Choi WI,Park YB,Kim DS,Jeong SH,Lee JH,Park MS

更新日期：2012-05-01 00:00:00

abstract：BACKGROUND:Most non-small cell lung cancer (NSCLC) patients relapse on anaplastic lymphoma kinase-tyrosine kinase inhibitor (ALK-TKI) therapy because of acquired resistance. Rebiopsy is recommended to provide optimal therapy after relapse for some ALK-TKI therapies; however, little clinical data exists on the clinical ...

journal_title：Thoracic cancer

authors： Haratake N,Seto T,Takamori S,Toyozawa R,Nosaki K,Miura N,Ohba T,Toyokawa G,Taguchi K,Yamaguchi M,Shimokawa M,Takenoyama M

更新日期：2019-09-01 00:00:00

abstract：BACKGROUND:Immunotherapy is a new paradigm for the treatment of non-small-cell lung cancer (NSCLC), and targeting the PD-1 or PD-L1 pathway is a promising therapeutic option. Although PD-1/PD-L1 inhibitors are more effective than standard chemotherapy in lung cancer, clinicians are afraid to actively use them because o...

journal_title：Thoracic cancer

authors： Kang DH,Chung C,Kim JO,Jung SS,Park HS,Park DI,Jung SY,Park M,Lee JE

更新日期：2018-11-01 00:00:00

abstract：:For refractory or resistant small cell lung cancer (SCLC), there is no standard treatment. We report a case of refractory SCLC achieving complete remission and then developing fatal interstitial pneumonitis after treatment with single-agent nab-paclitaxel. The relevant literature has also been reviewed. In terms of ef...

journal_title：Thoracic cancer

authors： Wang B,Yang J,Luo D,Qiao H,Xie Z,Zhang X,Wu Y

更新日期：2012-02-01 00:00:00

abstract：BACKGROUND:Malignant pleural mesothelioma (MPM) is an aggressive cancer refractory to current therapies. Reduced expression of micro ribonucleic acid (miR)-591 in a range of cancer types has suggested it is a potent tumor suppressor, and overexpression has been shown to inhibit tumor cell growth. The role of miR-591 in...

journal_title：Thoracic cancer

authors： Cheng S,Xu Y,Shi Z,Lin Y,Hoang CD,Zhang X

更新日期：2016-04-26 00:00:00

abstract：BACKGROUND:Non-small-cell lung cancer (NSCLC) is the most lethal type of cancer. Long non-coding RNAs (lncRNAs) and microRNAs (miRNAs) have been identified as crucial regulators in the development of NSCLC. The aim of our study was to explore the molecular mechanism of SNHG1 to enable better treatment for NSCLC patient...

journal_title：Thoracic cancer

authors： Li X,Zheng H

更新日期：2020-02-01 00:00:00

abstract：BACKGROUND:The purpose of this study was to investigate the risk factors of postoperative complications and reliable prognostic factors of long-term survival in HIV-infected patients with non-small cell lung cancer (NSCLC). METHODS:HIV-infected patients with NSCLC who underwent surgical treatment were retrospectively ...

journal_title：Thoracic cancer

authors： Wang L,Chen Y,Wang Y,Liu J,Wen Z,Chen H,Zhu Y,Wang J,Wan L,Li F,Song Y

更新日期：2020-08-01 00:00:00

abstract：BACKGROUND:As its etiology and pathogenesis is obscure, illustrating the molecular mechanism of lung cancer has become a serious and urgent task. Studies have shown that fumarate hydratase (FH) is a tumor suppressor related to tumorigenesis, development, and invasion. Our aim was to analyze the biological information o...

journal_title：Thoracic cancer

authors： Ming Z,Jiang M,Li W,Fan N,Deng W,Zhong Y,Zhang Y,Zhang Q,Yang S

更新日期：2014-11-01 00:00:00

abstract：:Immune checkpoint inhibitors (ICIs) activate host antitumor immunity to kill tumor cells. However, ICI therapy may be accompanied by a series of immunotherapy-related adverse effects (irAEs) caused by activated autoreactive T cells. Glucocorticoids are the mainstream therapy for irAEs. However, the usage, dosage and c...

journal_title：Thoracic cancer

authors： Wang H,Zhou J,Guo X,Li Y,Duan L,Si X,Zhang L

更新日期：2020-10-01 00:00:00

abstract：:Immunoglobulin light-chain (AL) amyloidosis is a monoclonal plasma cell neoplasm that has a tendency to bleed easily. However, the potential risks of transbronchial biopsy in such cases have not been fully proven. Here, we report a case of parotid and intrathoracic AL amyloid tumors that presented as endobronchial pro...

journal_title：Thoracic cancer

authors： Tomono H,Soda H,Fukuda Y,Tanaka Y,Ono S,Shimada M,Iwasaki K,Hisanaga M,Yamaguchi H,Mukae H

更新日期：2019-10-01 00:00:00

abstract：:Here, we report two cases of advanced non-small cell lung cancer (NSCLC) in patients with negative driver genes who received ICI treatment for less than two years but continued to benefit from their administration after drug withdrawal. The first patient was diagnosed with left lung adenocarcinoma, cT1cN3M1c, stage IV...

journal_title：Thoracic cancer

authors： Shan Q,Wang H,Han X,Guo J,Wang Z

更新日期：2020-10-01 00:00:00

abstract：BACKGROUND:Accumulated evidence has revealed that the dysregulation of micro ribonucleic acids (miRNAs) may contribute to esophageal squamous cell carcinoma (ESCC). MiR-93, which is a member of the miRNA cluster miR-106b∼25, has been widely studied for its tumor promoting effect on different types of cancers. However, ...

journal_title：Thoracic cancer

authors： Li C,Ding C,Chen T,Chen J,Xu Z,Lei Z,Xu C,Zhao J

更新日期：2015-07-01 00:00:00

abstract：BACKGROUND:Malignant pleural mesothelioma (MPM) is an aggressive tumor, associated with poor prognosis. There is a lack of information about the clinical and pathological features related with survival in the Latin American population. METHODS:The MeSO-CLICaP registry identified 302 patients with advanced MPM diagnose...

journal_title：Thoracic cancer

authors： Rojas L,Cardona AF,Trejo-Rosales R,Zatarain-Barrón ZL,Ramírez-Tirado LA,Ruiz-Patiño A,Campos Gómez S,Corrales L,Oblitas G,Bacon L,Martín C,de Lima VCC,Freitas HC,Mas L,Vargas C,Carranza H,Otero J,Pérez MA,González L,

更新日期：2019-03-01 00:00:00

abstract：BACKGROUND:The aim of this study was to investigate the feasibility of using a combination of apatinib in the treatment of non-small cell lung cancer. Apatinib is a tyrosine kinase inhibitor which selectivelyacts on vascular endothelial growth factor receptor 2 (VEGFR-2) and has shown good efficacy in a variety of mali...

journal_title：Thoracic cancer

authors： Liu M,Wang X,Li H,Xu L,Jing L,Jiang P,Liu B,Li Y

更新日期：2019-10-01 00:00:00

abstract：BACKGROUND:Vagus nerve and recurrent laryngeal nerve (RLN) injury are not rare complications of lung cancer surgery and can cause lethal consequences. Until now, no optimal method other than paying greater attention during surgery has been available. METHODS:Four patients underwent lung surgery that involved RLN or va...

journal_title：Thoracic cancer

authors： Li H,Hu Y,Huang J,Yang Y,Xing K,Luo Q

更新日期：2018-05-01 00:00:00

abstract：BACKGROUND:The prognostic values of preoperative neutrophil/lymphocyte ratio (NLR), monocyte/lymphocyte ratio (MLR), and platelet/lymphocyte ratio (PLR) in non-small cell lung cancer (NSCLC) have been previously described. This study assessed the prognostic values of other pretreatment complete blood cell parameters in...

journal_title：Thoracic cancer

authors： Yuan C,Li N,Mao X,Liu Z,Ou W,Wang SY

更新日期：2017-07-01 00:00:00

abstract：BACKGROUND:Several studies have previously demonstrated the survival benefit of both EGFR-TKI treatment and chemotherapy in patients with non-small cell lung cancer (NSCLC) harboring EGFR mutations. The aim of the present study was to clarify the factors influencing the treatment sequence after failure of EGFR-TKI ther...

journal_title：Thoracic cancer

authors： Mizuno T,Horinouchi H,Watanabe S,Sato J,Morita R,Murakami S,Goto Y,Kanda S,Fujiwara Y,Yamamoto N,Ohe Y

更新日期：2020-04-01 00:00:00

abstract：:We report a case of primary inflammatory myofibroblastic tumor of the diaphragm in a 64-year-old man. The patient was hospitalized for a computed tomography (CT)-detected large tissue mass at the left lower lung field. Complete tumor excision followed by pathological investigation was performed. Microscopically, the t...

journal_title：Thoracic cancer

authors： Fu J,Wu Q,Zhang Y,Zhang X,Wang Z

更新日期：2013-11-01 00:00:00

abstract：BACKGROUND:This study aims to evaluate the incidence and characteristics of chyle leakage after curative oncologic esophagectomy, and the effectiveness of thoracic duct ligation. METHODS:This is a retrospective cohort study using the medical records of 1514 patients who underwent curative esophagectomy for esophageal ...

journal_title：Thoracic cancer

authors： Kim D,Cho J,Kim K,Shim YM

更新日期：2014-09-01 00:00:00

abstract：BACKGROUND:If anaplastic lymphoma kinase (ALK) gene rearrangement in lung cancer is identified, ALK-tyrosine kinase inhibitors (ALK-TKIs) can be an effective treatment. However, the details of drug-induced lung injury (DILI) caused by ALK-TKI, which can be a serious side effect of ALK-TKIs, remains unclear. This study ...

journal_title：Thoracic cancer

authors： Koshikawa K,Terada J,Abe M,Iwasawa S,Sakayori M,Yoshioka K,Hirasawa Y,Kasai H,Kawasaki Y,Tsushima K,Tatsumi K

更新日期：2020-06-01 00:00:00

abstract：BACKGROUND:Lung cancer is a disease with a poor prognosis and psychological impact. Lung cancer causes both physical and psychological burdens on patients, and financial burdens on families and society. The aim of this study was to examine the relationship between depression and influencing factors in non-small-cell lu...

journal_title：Thoracic cancer

authors： Shi Y,Gu F,Hou LL,Hu YQ

更新日期：2015-05-01 00:00:00

abstract：:Programmed cell death-1 immune checkpoint inhibitor (ICI) antibody has proven to be effective in advanced non-small cell lung cancer (NSCLC) patients positive for programmed cell death-1 ligand-1. However, there are currently no reports which evaluate drug efficacy by continuous bronchoscopic observation. A 75-year-ol...

journal_title：Thoracic cancer

authors： Morikawa K,Kida H,Handa H,Inoue T,Miyazawa T,Mineshita M

更新日期：2020-05-01 00:00:00

abstract：BACKGROUND:Approximately 15% of lung cancer patients are diagnosed in early stages. Microscopic proof of disease cannot always be obtained because of comorbidity or reluctance to undergo invasive diagnostic procedures. In the current study, survival data of patients with and without pathology are compared. METHODS:One...

journal_title：Thoracic cancer

authors： Zehentmayr F,Sprenger M,Rettenbacher L,Wass R,Porsch P,Fastner G,Pirich C,Studnicka M,Sedlmayer F

更新日期：2019-02-01 00:00:00

abstract：BACKGROUND:This meta-analysis was conducted to investigate the diagnostic performance of P16INK4a gene promoter methylation as a biomarker of non-small cell lung cancer (NSCLC). METHODS:Two reviewers independently searched the Web of Science, PubMed, Cochrane, Embase, China National Knowledge Infrastructure, and Chine...

journal_title：Thoracic cancer

authors： Tuo L,Sha S,Huayu Z,Du K

更新日期：2018-08-01 00:00:00